Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

Overview of attention for article published in BMC Neurology, June 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 2,482)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 5 X users

patent: 5 patents
facebook: 1 Facebook page
googleplus: 1 Google+ user

Citations

dimensions_citation: 107 Dimensions

Readers on

mendeley: 122 Mendeley

Summary News Blogs Policy documents X Patents Facebook Google+ Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis

Good Day Sacramento, 23 Jul 2015

Independent Data Safety Monitoring Committee recommends continuation of phase 3 study based on review of safety and efficacy…

AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis

Biospace, 23 Jul 2015

Independent Data Safety Monitoring Committee recommends continuation of phase 3 study based on review of safety and efficacy…

AB Science announces successful non futility test for masitinib in progressive forms of multiple sclerosis

Town Hall, 23 Jul 2015

Independent Data Safety Monitoring Committee recommends continuation of phase 3 study based on review of safety and efficacy…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.